UNIVERSITY OF MICHIGAN W.K. KELLOGG EYE CENTER Innovation for the Future

ANNUAL REPORT 2 018 TEAMWORK

INTEGRITY

INNOVATION

CARING Innovation for the Future University of Michigan Kellogg Eye Center Annual Report 2018

5 8 15 18 25

Table of Contents Enhancing the Way We Educate Research to Create Tomorrow's and Learn Advances 2 The Chair’s Perspective 15 Aravind Leader Challenges 23 Research Update Advancing Patient Care Perspectives Philanthropy is Crucial to 3 Gene Therapy 16 Strengthening Our Residency Partnership in Ethiopia Our Success 8 Restoration of Eye Sensation 28 Faculty Named to Two 16 Retinal Dystrophy in Puducherry 9 Developing the Future of eHealth Endowed Professorships 17 Kellogg Hosts First U.S. 29 Victors for Michigan, 10 Providing Complex Care Closer Meeting of World Association Victors for Vision to Patients and Communities of Eye Hospitals

11 Applying Precision Medicine 18 A Pipeline to Greater Diversity Our Kellogg Family: to Glaucoma in Ophthalmology Faculty and Trainees

12 Personalizing Complex Care 19 Diversity, Equity and Inclusion 30 New Faculty 13 Clinical Research Update Guest Lectureship: Eve Higgenbotham, SM, MD 31 Graduating Residents and Fellows 17 Safer Cataract Surgery 19 The 2018 Farjo Lecturer: 32 First Year Post-Doctoral Fellows Roy W. Beck, MD, PhD 33 Michigan Alumnus Honored for 20 Paying It Forward Humanitarian Efforts in Africa Front cover clockwise from top: Ariane Kaplan, MD with a Michigan medical student, 21 Alumni Spotlight 33 First Year Residents Scott Lawrence, MD, Jillian Pearring, PhD, Emma Roden, Sayoko Moroi, MD, PhD, Thulasiraj 22 Recipients of the 2018 34 Faculty Honors and Recognition Ravilla, David Abcouwer, PhD center: Shannon Joseph, MD Champalimaud Vision Award Include Dr. Robin Ali, PhD 38 Kellogg Eye Center Faculty Thomas Gardner, MD, MS, associate chair for research, Roni Shtein, MD, Ann Arbor ACU director and Medical Director of the ORs, Alan Sugar, MD, MS, vice chair and associate chair for clinical affairs, Paul Lee, MD, JD, chair, Shahzad Mian, MD, associate chair for education, Denise John, MD, director of VA Hospital Eye Care, and Thiran Jayasundera, MD, director of strategic planning

The Chair’s Perspective

Dear Friends and Colleagues,

We are in an incredible time of scientific and educational and we are cultivating our evidence-based eHealth and progress in the world of eye care and research. Advances in telemedicine programs to further transform and expand understanding mechanisms of visual function and disease, how we care for patients. the implementation of an FDA approved gene therapy, and Today’s care increasingly combines the expertise of the growth of eHealth are some of the ongoing exciting work specialties within ophthalmology and with other fields of in vision care and research. In this year’s Annual Report, we medicine. By also drawing upon the knowledge and skills are pleased to share contributions of our faculty, trainees, staff, of our colleagues in other disciplines outside of medicine, and partners from around the world. we can continue to create better systems that improve patient Kellogg is one of ten eye centers selected to offer the first safety and effectiveness of care. FDA-approved gene therapy treatment for correcting mutations Kellogg strives to integrate research, teaching and clinical in the RPE65 gene. Several gene therapy trials for other care to improve the lives of patients and their families. The inherited eye diseases are currently underway at Kellogg and progress detailed in this report was achieved with the support a number of centers. These gene therapy—and the many of our friends and colleagues combined with the dedication, other—clinical trials at our Kellogg Clinical Research Center imagination and commitment of our Kellogg faculty, staff affirm that research is being translated into new treatments and trainees. We look forward to the amazing progress to that may improve the lives of many. come in 2019! Tomorrow’s new treatments come from today’s basic research—a focus of the National Eye Institute and many of our Kellogg scientists. Ongoing bench research into the fundamental biology of how the visual system works is an investment in future treatments and cures. Paul P. Lee, MD, JD Research advances, once they have been thoroughly tested F. Bruce Fralick Professor and and approved, only help our patients if they have access to Chair, Ophthalmology and Visual Sciences them. We are working to make complex care more readily Director, W.K. Kellogg Eye Center available in communities closer to where our patients live,

2 Advancing Patient Care

3 Kellogg Offers New Gene Therapy Options For Treating Inherited Retinal Dystrophies

A long list of retinal dystrophies, including retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis (LCA), achromatosopia, X-linked retinoschisis, Usher syndrome and choroideremia, can be traced to inherited changes in DNA. All of these conditions lead to progressive vision loss; some end in total blindness. Until very recently, these wide-ranging disorders shared one thing in common: there were no available treatments for them. Today, advances in gene therapy are finally yielding new options that may revolutionize the treatment of inherited retinal degenerations, giving retinal specialists new tools and patients and families new hope.

4 ULTIMATELY, WE WANT THESE THERAPIES TO BE AVAILABLE FOR OUR YOUNGEST “PATIENTS. THE SOONER THEY RECEIVE TREATMENT, THE LESS VISION LOSS THEY

MAY HAVE TO ENDURE.” — Cagri Besirli, MD, PhD

5 Thiran Jayasundera, MD, FACS, and Emma Roden, a patient undergoing evaluation for gene therapy

Retinal cells in inherited retinal disorders do not function In fact, Luxturna™ is the only FDA-approved gene replace- normally due to a gene defect. In gene replacement therapy, a ment therapy for any human disease linked to a genetic change. working copy of a gene is embedded in a virus that is injected Kellogg is one of ten treatment centers in the country approved into the vitreous or under the retina. The virus delivers the to offer the treatment, and Dr. Cagri Besirli, MD, PhD, antici- correct DNA to the affected retinal cells. pates that patients at Kellogg will receive injections soon. While the majority of gene therapy options are still in Gene therapy is anything but simple; it takes an extraordi- experimental trials to confirm their safety, efficacy, and dosing, nary team effort to get these treatments to the patients who the FDA has approved one gene therapy, Luxturna™ (voretigene need them. Kellogg is one of the few centers in the U.S. with neparvovec-rzyl) to correct a defect in the gene RPE65 that the multidisciplinary expertise to offer this new generation of leads to Leber Congenital Amaurosis. gene therapy clinical trials for other conditions.

6 WE HAVE AN FDA-APPROVED TREATMENT FOR ONE CONDITION AND NUMEROUS PROMISING OPTIONS FOR OTHERS. WE HAVE AN OUTSTANDING RETINAL “DYSTROPHY TEAM, AND WE HAVE AMAZING PATIENTS. ” — Cagri Besirli, MD, PhD

Kellogg’s team of retinal specialists devoted to the diagnosis and management of patients with inherited retinal disorders includes Cagri Besirli, MD, PhD, Abigail Fahim, MD, PhD, and K. Thiran Jayasundera, MD, FACS. Dr. Besirli, a pediatric Cagri Besirli, MD, PhD retinal surgeon, serves as principal investigator of several ongoing therapeutic trials. “Ultimately, we want these therapies to be available for our youngest patients,” he explains. “The sooner they receive treatment, the less vision loss they may have to endure.” Dr. Jayasundera is the principal investigator on research that precedes clinical testing, called natural history studies (NH). “NH studies collect and analyze patient information to draw a clearer picture of how these disorders develop and progress,” he explains. “NH is especially important for design- ing clinical trials of new treatments for these diseases.” Other critical members of the team include Kellogg electrophysiologists, led by Naheed Khan, PhD, whose work guides both diagnosis and treatment; genetic counselors Kari Branham, MS, CGC, and Dana Schlegel, MS, MPH, CGC, who help families navigate the complexities of their disease; Adrienne Chen, PhD; and the staff of the Kellogg Clinical Research Center (KCRC). Branham and Schlegel are two of only about 50 genetic counselors in the world dedicated solely above: Naheed Khan, PhD, meets with a Emma as she undergoes testing. to ophthalmology. Kellogg is also fortunate to work with below: Kari Branham, MS, CGC, meets with Emma and her family Professor Robin Ali, of the University College of London, and to help determine if she is eligible for the treatment his team on these efforts. Kellogg is currently conducting gene therapy clinical trials and natural history studies for a range of inherited retinal condi- tions. Dr. Besirli is excited to be part of the group bringing gene therapy to patients at Kellogg. “For so long, we’ve struggled to help patients facing these blinding illnesses,” he says. “Gene therapy is still in its infancy, but there is reason for optimism. We have an FDA-approved treatment for one condition and numerous promising options for others. We have an outstanding retinal dystrophy team, and we have amazing patients. It’s a very exciting time.”

7 Shannon Joseph, MD, and Christopher Hood, MD, worked together to help Lou Ann Davis-Walter regain corneal sensation. In addition to Kellogg Drs. Joseph, Mian and Hood, the team includes David Lawrence Brown, MD, and Steve Kasten, MD, from the U-M Department of Surgery, and Jennifer Kim, MD, and Andrew Joseph, MD, from the U-M Department of Otolaryngology.

Kellogg Offers Minimally-Invasive Procedure to Restore Eye Sensation

Michigan Medicine surgeons are helping patients who have lost The novel treatment places new nerves around the cornea sensation in their cornea regain feeling through a small-incision to restore sensation. Dr. Joseph, the oculoplastic surgeon on the nerve transplant procedure called corneal neurotization. team, explains how it works: “A nerve graft is harvested from Patients who have lost sensation in the eye due to a elsewhere in the patient’s body to act as a conducting cable for congenital condition, a viral infection, diabetes, trauma, nerve signals. One end of this cable is connected to the nerve cancer or surgery can develop a condition responsible for sensation in the forehead, called neurotrophic keratopathy. “By restoring corneal sensation, and the other end is then wrapped around “With reduced ability to feel eye pain or and tunneled into the cornea.” these patients will be much better irritation, these patients are unable to protect The graft serves as a scaffold through their eyes from everyday hazards like dust, candidates for transplantation to which new nerves develop, millimeter by debris and wind by blinking,” explains Kellogg millimeter, until they grow into the cornea. regain their sight.” cornea specialist Shahzad Mian, MD. “As a “We’re able to perform the procedure through result, they are more likely to develop corneal — Shahzad Mian, MD very small incisions that hide in the crease of scratches and severe dry eye that can progress the eyelid, making it virtually unnoticeable,” to infections, ulcerations and scarring. Left untreated, these she adds. Over the course of the next several months, sensation issues can lead to vision loss.” in the eye gradually returns. Cornea specialist Christopher Hood, MD, oculoplastic “For patients who have really suffered, this can be life- surgeon Shannon Joseph, MD, and Dr. Mian lead a team of changing,” says Dr. Hood. “It’s tough to manage neurotrophic experts in ophthalmology and visual sciences, plastic surgery keratopathy with drops, contact lenses or patches. In some and otolaryngology, to perform a minimally invasive surgical cases, we have performed a tarsorrhaphy—a procedure to join procedure to address neurotrophic keratopathy called corneal the eyelids—to give affected eyes a chance to heal. With this neurotization. Michigan is one of the few hospitals in the coun- procedure, we can address the underlying cause of the problem.” try, and the only one in the state, offering this option.

8 Developing the Future of eHealth

For underserved populations, proximity to specialty medicine Dr. Woodward works alongside a team of eHealth experts can be a big problem. Kellogg’s eHealth program will provide at Kellogg, including Rebecca Wu, MD, Clinical Director for the a way for these underserved patients to receive essential care eHealth Diabetic Eye Program, eHealth program Co-Director without having to travel to the specialist’s office. The eHealth Paula Anne Newman-Casey, MD, MS, and Beth Hansemann, program focuses on ways to screen and monitor diabetic eye BS, COT, continuous improvement specialist. Other Kellogg disease, glaucoma, cataracts, corneal infection, retinopathy of faculty include Dr. Cagri Besirli, who leads eHealth work on prematurity, and macular degeneration. retinopathy of prematurity screening; Dr. Christine Nelson, “All telemedicine and eHealth programs first will be tested who is kickstarting an eHealth program in oculoplastics; and to make sure they are safe and effective for patients,” says Dr. Hakan Demirci, who has been exploring eHealth to provide Mia Woodward, MD, MS, Assistant Professor of Ophthal- ocular oncology care to resource-challenged settings. Blair mology and Visual Sciences and Co-Director of the eHealth Snyder, COA, provides electronic medical record support to the program. “Telemedicine offers convenient care and better team. Kellogg residents and alumni have also made significant access for Michigan patients, but we must maintain a high contributions to the field, including Drs. Crandall Peeler, Tyson quality of care.” Kim and Tapan Patel.

ETELEMEDICINE OFFERS CONVE- NIENT CARE AND BETTER ACCESS FOR MICHIGAN PATIENTS, BUT “WE MUST MAINTAIN A HIGH

QUALITY OF CARE.” — Mia Woodward, MD, MS

Kellogg's eHealth team includes, clockwise from left: Paula Anne Newman-Casey, MD, MS, Christine Nelson, MD, Beth Hansemann, BS, COT, Blair Snyder, COA, Rebecca Wu, MD, Mia Woodward, MD, MS

The team also inculeds Hakan Demirci, MD, and Cagri Besirli MD, PhD

9 Providing Complex Care Closer to Patients and Communities

The newly opened Brighton Center for Specialty Care

Kellogg eye surgeons can now offer a high level of specialty eye care outside of the main location in Ann Arbor, bringing care closer to the patients who need it at the newly opened Michigan Medicine’s Brighton Center for Specialty Care. Brighton joins West Ann Arbor, Northville, Canton, Briarwood, and Chelsea as community locations where Michigan Medicine has integrated multi-specialty clinics. Kellogg also has two ophthalmology-only offices offering specialty eye care in Milford and East Huron River Drive (Ypsilanti). Patients no longer need to travel so far to receive multispecialty eye care. “Because of our expanded footprint, we are able to offer more patients easier and timelier access to specialty eye care,” says Shivani Kamat, MD, a clinical instructor of ophthalmology and visual sciences, the medical director at the Brighton facility. The Brighton clinic offers minimally invasive eye surgery, complex eye procedures, and laser technology. Kellogg ophthal- mologists at the facility include those who specialize in cornea and refractive surgery, glaucoma, retina, pediatrics, and oculoplastics. “We have added physicians and have a large, state-of-the- art clinic that houses all the diagnostic and therapeutic tools that patients may need,” says Dr. Kamat. Shivani Kamat, MD, examines a patient at the Brighton Center for Specialty Care “We have many patients with transportation issues,” says Joshua P. Vrabec, MD, clinical assistant professor of ophthalmol- ogy and visual sciences, who practices at the Northville Health Center. “Our patients are much happier with local services.”

10 Mia Woodward, MD, MS, brings subspecialty cornea care to her patients at the Northville Health Center

Applying Precision Medicine to Glaucoma

Detecting large intraocular pressure (IOP) fluctuations remains a critical challenge in treating patients with glaucoma. This IOP variation and the peak measurement of IOP predict who will have glaucoma damage and related vision loss. Sayoko Moroi, MD, PhD, along with team members at Kellogg, the Mayo Clinic, the University of Nebraska, and Case Western Reserve University have worked to integrate these tools toward personalizing IOP treatment for glaucoma. Funded by the National Eye Institute and other agencies, Dr. Moroi and her team have characterized the “inflow”, “outflow” and blood vessel factors that influence IOP changes over time. In the next study phase, Dr. Moroi and her team will measure IOPs at home to gain real world data outside of clinic hours. Preliminary home IOP data have identified patients with high home IOPs that were measured as normal during clinic visits. By understanding the factors responsible for IOP variation, Dr. Moroi hopes to target those with the greatest fluctuation or highest IOPs for more intensive care. A related translational project is to map the eye fluid drain- age pathways, which is recently funded by the National Science Foundation with UM Engineer Dr. Alan Argento. Characterizing a patient’s eye fluid drainage map will help us understand the variable IOP outcomes patients experience with the new

“microinvasive glaucoma surgeries” or MIGS. The results will Sayoko Moroi, MD, PhD, demonstrates the Icare Home Tonometer to her patient advance our understanding of the complex biology of IOP and lead toward a personalized IOP-based treatment for patients.

11 EYE CARE PRACTITIONERS CAN REDUCE THE RISK OF CORNEAL TRANSPLANTATION FAILURE BY “WORKING CLOSELY WITH TEAM PARTNERS IN RHEUMATOLOGY AND USING SYSTEMIC IMMUNE

SUPPRESSION.” — Shahzad Mian, MD

Shahzad Mian, MD, examines patient Linda Bunker

Personalizing Complex Care

After a 30-year battle with viral outbreaks that caused scarring “She had inflammation and significant vision loss from in her cornea, Linda Bunker met a multidisciplinary team at corneal scarring. Also, the infection may have spread deeper the Kellogg Eye Center that successfully performed a corneal into the eye by the time she came to us,” says Dr. Mian. transplant. “Most patients who come to us have less severe disease." An outbreak of a viral infection in the eye can be serious, Due to her complex situation another expert was enlisted– progressing deep into the eye and possibly leading to the loss Rheumatologist April Marquardt, OD, MD, Adjunct Clinical of the eye, says Shahzad Mian, MD, Ophthalmology Professor Assistant Professor of Rheumatology at UM. at UM and Associate Chair for Education. Infections in the Dr. Marquardt’s background in optometry is very unusual cornea, or keratitis, may be caused by viruses, bacteria, or for a rheumatologist, and that makes her a particularly valuable injuries. These infections can cause severe ulcers that result in member of the team. Dr. Marquardt regularly sees patients at scarring, abnormal blood vessels that invade the cornea, and Kellogg. “As a rheumatologist and optometrist, I understand nerve damage. These complications can increase the chances of the role that immunosuppression medications can play in the rejection and failure of a corneal transplant, says Dr. Mian. prevention of transplant rejection,” says Dr. Marquardt. In the past, Ms. Bunker had responded to treatments of She prescribed and monitored systemic medication to topical antiflammatory drugs and oral antiviral drugs. However, reduce the risk of rejection and improve the chances of trans- the outbreak that Dr. Mian saw was more serious, and included plant success. After Ms. Bunker’s eye was stabilized, a corneal a bacterial infection on top of her viral one. Due to her past transplant was performed and there were no issues with viral infections and current bacterial infection, she was at a rejection. higher risk for rejection if she underwent the corneal transplant “This week, the patient told me that she can see better she needed. than she could ever see in her life. Her vision is 20/30, 2 years after surgery,” says Dr. Marquardt.

12 CLINICAL RESEARCH UPDATE The Kellogg Clinical Research Center (KCRC) continues to exceed expectations. Grant Comer, MD, MS and Lindsay Godsey, MS, COA, work with Delores Price, a patient participating in one of the ongoing studies Associate Professor Grant Comer, MD, MS, medical director of the KCRC, was instrumental in developing the space and the team. “Our vision was to expand Kellogg’s clinical research enterprise by streamlining and simplifying the whole process for both researchers and participating patients.” The KCRC has more than realized that vision. Since OUR VISION WAS TO EXPAND KELLOGG’S opening its doors, clinical trial volume in ophthalmology has increased by more than 80 percent, including a number of high- CLINICAL RESEARCH ENTERPRISE BY ly complex gene therapy and stem cell therapy trials. “At the same time,” adds Dr. Comer, “we are an important partner for STREAMLINING AND SIMPLIFYING THE Michigan Medicine researchers in other specialties—from pedi- “WHOLE PROCESS FOR BOTH RESEARCHERS atrics to cancer—providing support for about 40 studies that require vision screening or monitoring for their participants.” AND PARTICIPATING PATIENTS.” The KCRC conducts a variety of studies ranging from — Grant Comer, MD, MS natural history studies to novel treatment trials. Studies span all sections within the Kellogg Eye Center, in hopes of better understanding eye conditions and discovering new ways to help as many of our patients as possible.

$13M 195,334 8,901 RESEARCH PATIENT VISITS SURGICAL FUNDING AT KELLOGG PROCEDURES

13 Enhancing the Way we Educate and Learn

14 Kellogg’s international leaders, from left: Jonathan Trobe, MD, Paul Lee, MD, JD, Thulasiraj Ravilla, Joshua Ehrlich, MD, MPH, Christine Nelson, MD, and H. Kaz Soong, MD Aravind Leader Challenges Perspectives

Kellogg’s Joshua Ehrlich, MD, David Musch, PhD, MPH, and Alan Robin, MD, met in Madurais, India with key leadership of the Aravind Eye Care System to develop a sustainable long-term research program. The program will train future clinician-scientists to tackle important questions related to vision, eye care delivery, and eye disease in India, including hands-on work through a didactic program involving mentored research projects, scientific writing, grant applications, and biostatistics.

The University of Michigan and the Aravind Eye Care System, through with the recommended surgery, medication or glasses. India’s largest private eye care hospital, have collaborated Changing these statistics requires a dramatic change in perspec- to cross-train providers, researchers and operational leaders tive, he argues. “If you don’t own the problem, you won’t make through a partnership that dates back nearly 40 years. This a difference.” year’s International Night attendees heard from Aravind’s The success of Aravind in India is a story of owning the Director of Operations, Thulasiraj "Thulsi" Ravilla. His problem. Thulsi described how Aravind has transformed their remarks, titled “Eliminating Needless Blindness—It’s All approach to these issues by eliminating barriers to care, includ- About Perspectives,” challenged us to see the delivery of ing rethinking the costs of care to better reflect opportunity vision care services in a new way. costs—food, transportation and lost wages—and how the Thulsi is also Executive Director of Lions Aravind Institute hospital views the delivery of care as a moral imperative. of Community Ophthalmology, Founder and President of As a result of countless evidence-based innovations touch- Vision 2020 India: The Right to Sight, a global initiative for the ing every aspect of the organization, Aravind has revolutionized elimination of blindness, and a visiting scholar at Michigan in the delivery of eye care in India, with programs such as commu- 1982. After nearly four decades in the field, he has concluded nity-based eye centers run by technicians, linked by telemedicine that how you view a health problem like cataract-related blind- to physicians. Remarkably, in the process, the organization has ness drives the design of services to address that problem. become financially viable, funding continuing growth through In developing nations, Thulsi estimates that for every substantial savings. “By doing good,” says Thulsi, “we are patient that seeks care, four or five do not, and for every patient doing well.” who receives treatment advice, as many as half may not follow 15 Strengthening Our Residency Partnership in Ethiopia

The fledgling ophthalmology residency program at Ethiopia’s St. Paul Hospital Millennium Medical College (SPHMMC) is growing in size and scope. In 2015, Kellogg ophthalmology joined a growing number of U-M Medical School departments committed to establishing long term in-country training partnerships with SPHMMC in Addis Ababa, Ethiopia. U-M Adjunct Professor of Obstetrics and Gynecology, Senait Fisseha, MD, JD, a native Ethiopian, has served as a the faculty and residents there, laying the groundwork for a catalyst for many of these initiatives. Her vision of applying comprehensive residency program. a train-the-trainer approach to move toward self-sufficiency A major step in that direction came this past year, when in education resonated with leadership at the Kellogg Eye Scott Lawrence, MD, was recruited to be Kellogg’s man on the Center for International Ophthalmology (KECIO). ground at St. Paul’s. Dr. Lawrence, a glaucoma specialist, has “Brain drain is a huge challenge in Ethiopia,” says lived and practiced in Ethiopia for more than three years. A Christine Nelson, MD, Professor of Ophthalmology and Clinical Associate Professor at Kellogg, Dr. Lawrence previously KEICO co-director. “They’ve had training programs in the directed an Association of University Professors of Ophthalmol- past, but people would come to the States for training and ogy certified glaucoma fellowship, and coordinated advanced then never return.” The program hopes to change that. training in cataract and glaucoma surgery. “Scott has already Thanks to the commitment and persistence of numerous made an enormous contribution to the program,” says Kellogg colleagues, the ophthalmology residency program Dr. Nelson. “We’re so fortunate to have him on the team.” established at SPHMMC has grown to 23 residents and ten The pace of progress at St. Paul’s is not lost on Dr. Nelson. faculty members. The next phase in the program’s evolution: “The first time I visited, I operated by the flashlight on my focus on training in sub-specialties. Kellogg faculty specializing phone during a power outage,” she recalls. “Now, we’re ready in oculoplastic surgery, pediatric ophthalmology, retinal surgery to graduate the first class of residents. In a short time, we’ve and ocular ultrasound have all traveled to St. Paul’s to mentor come a long way together.”

Retinal Dystrophy in Puducherry

In 2015, Kellogg’s Naheed Khan, PhD, partnered with Dr. Pankaja Dhoble, MD, to build a retinal dystrophy clinic and electrophysiology lab at the Puducherry branch of Aravind Eye Hospital (AEH). Since that time, Dr. Khan has organized and facilitated a training process for Dr. Dhoble with the retinal dystrophy team at the Kellogg Eye Center. A complementary process to provide genetic testing was also established between Dr. Dhoble and Dr. P. Sundaresan, a genetic specialist at AEH. The ultimate goal of this collaboration is the development of a comprehensive clinical care center at Aravind Eye Hospital for retinal dystrophy patients, which will both further the diagnosis and treatment of patients and provide rich opportunities for ongoing scientific collaborations.

16 Kellogg Hosts First U.S. Meeting of World Association of Eye Hospitals

The Kellogg Eye Center and Michigan Medicine recently welcomed eye hospital leaders from around the globe as the World Association of Eye Hospitals (WAEH) brought its annual meeting to the U.S. for the first time. Almost 150 ophthalmologists and top-level administrators from six continents participated in the four-day annual meeting, organized by Kellogg Eye Center for International Ophthal- mology Administrative Director Donna Donato and Professor University of Michigan President Mark Schlissel, MD, PhD, spoke at the Christine Nelson, MD. World Association of Eye Hospitals meeting at Kellogg Kellogg was the first U.S. hospital to join the WAEH in 2015. Since then, more than 12 other US centers have joined development, finance and more. A significant discussion about the WAEH. While there were meeting sessions devoted to clini- enhancing patient safety, particularly during cataract surgery, cal practice and research, the agenda included topics related to was led by Professor James Bagian, MD, PE, of the Michigan building, growing and managing a premier eye center, including College of Engineering, and colleagues from the Moorfields Eye administration, operations, patient safety, tele-ophthalmology, Hospital in London and the Singapore National Eye Center. workplace culture, philanthropy and fundraising, staff

Safer Cataract Surgery

Cataract surgery is the most common surgical procedure in ophthalmology. Although the vast majority of procedures are successful, the complexity inherent in cataract surgery increases the potential for a mistake to occur. The Kellogg Eye Center recently embarked on a compre- hensive review of all steps involved in cataract surgery, in order to make the procedure safer for patients and ensure the highest quality of care. “This is a very deep dive into our process,” explains Jennifer Weizer, MD, associate professor and director of the Kellogg quality improvement team. “We’re looking at every step to identify and address vulnerabilities before errors or even close calls occur.” Based on an approach first developed to improve safety in military and manufacturing settings, Kellogg adopted a hybrid model developed for healthcare by the Department of Veterans Affairs National Center for Patient Safety. Assisted by colleagues from Michigan Medicine and the College of Engineering, a working group was formed, including The implementation phase, currently underway, focuses on 23 faculty and staff involved in every aspect of cataract translating the recommendations into a consistent approach to surgery. “Based on our analysis, we recommended 34 separate all cataract surgeries at Kellogg. Continuous observation changes to make cataract surgery less vulnerable to human will ensure that the changes positively impact outcomes. error” says Dr. Weizer.

17 “The idea is to expose medical students to ophthalmology A Pipeline to Greater early in their studies,” explains clinical assistant professor Ariane Kaplan, MD, who, as part of a DEI committee that Diversity in Ophthalmology includes department faculty, medical students and staff, oversees the program. “If they decide to pursue ophthalmology, their To better serve our communities, we should mentors can continue supporting them all the way through the better reflect our communities. very competitive and stressful process of applying for residency.” Why pair newcomers with newcomers? Dr. Kaplan cites Studies show that patients are more likely to trust healthcare two reasons. “First, both are negotiating new, albeit different physicians with whom they share similar ethnic backgrounds environments with steep, intimidating learning curves, so it and cultural experiences. fosters a strong sense of being in it together. And residents Minority underrepresentation is especially pronounced in can be more approachable and relatable than faculty, having ophthalmology. Just six percent of practicing ophthalmologists just ‘survived’ medical school themselves.” and eight percent of ophthalmology residents identify as African The program launched during the 2017-2018 academic American/black, Native American, or Hispanic, compared to year, pairing nine mentees with seven first year ophthalmology roughly 30 percent of the U.S. population. residents. “The feedback we’ve received is very positive, and A novel effort at the Kellogg Eye Center is working to close some mentees have expressed an interest in pursuing ophthal- the gap. The Mentorship-led Pipeline Program, part of Kellogg’s mology,” says Dr. Kaplan. The existing pairings will continue, and Diversity, Equity and Inclusion (DEI) initiative, combines peer a class of seven new applicants will be matched with mentors. relationships, clinical experience, skill building and social events An Innovation Grant through the U-M Office of Diver- to encourage underrepresented medical students to explore sity, Equity and Inclusion provided funding for the 2017-2018 careers in ophthalmology. The program is unique because it academic year. Current academic year funding from a Rackham pairs incoming medical students with first-year ophthalmology Faculty Allies and Student Ally Diversity Grant and a Michigan residents. Medicine DEI Mini-grant will allow the program to expand in the year ahead.

IF THEY DECIDE TO PURSUE OPHTHALMOLOGY, THEIR MENTORS CAN CONTINUE SUPPORTING “THEM ALL THE WAY THROUGH THE VERY COMPETITIVE AND STRESSFUL PROCESS OF

APPLYING FOR RESIDENCY.” — Ariane Kaplan, M.D.

18 Elizabeth Parrish, COA, Bernadete Ayres, M.D., and Tanya McClendon-Hubbard, COA

WE NEED TO THINK BROADLY AND USE EVIDENCE MINDFULLY. WE NEED TO SEE OUR PATIENTS AS FAR MORE THAN THE SYMPTOMS THEY PRESENT. WE NEED TO UNPACK THE HIDDEN FACTORS DRIVING “NOT JUST OUR PATIENTS, BUT OUR COLLEAGUES, OUR COMMUNITIES

AND OURSELVES.” — Eve Higginbotham, SM, MD

Eye Center when she was a faculty member at Michigan. Diversity, Equity and “Dr. Higginbotham is a true leader in combining clinical Inclusion Guest Lectureship: and public health research to improve the health of individuals and communities, “ says Kellogg Director Paul P. Lee, MD, JD. Eve Higginbotham, SM, MD “It’s wonderful to welcome her back to share her insights and wisdom.” Using the backdrop of a patient case, Dr. Higginbotham’s In April, Kellogg’s Diversity, Equity and Inclusion (DEI) commit- presentation, Unpacking the Hidden Factors Shaping the Care tee sponsored a grand rounds presentation by guest lecturer and of Our Patients, challenged residents and medical students to Kellogg faculty alumna Eve Higginbotham, SM, MD. see the practice of ophthalmology from multiple perspectives: A glaucoma specialist, Dr. Higginbotham is the inaugural the patient, the physician, the medical practice and the commu- Vice Dean for Inclusion and Diversity of the Perelman School nity. Through an evidence-based lens, she examined each, citing of Medicine at the University of Pennsylvania, Senior Fellow at research into factors as wide-ranging as patient perceptions, the the Leonard Davis Institute for Health Economics and Professor impact of comorbidities, physician bias, motivators and barriers of Ophthalmology at the University of Pennsylvania. Recently in practices, and the moral imperatives and economic disparities adding to her impressive list of career milestones, she was elect- of communities. ed President of the AΩA Medical Honor Society in 2017 and “To deliver the best care,” says Dr. Higginbotham, “we was elected to the Council of the National Academy of Medicine need to think broadly and use evidence mindfully. We need to in 2018. She is also a Vice Chair of the Ocular Hypertension see our patients as far more than the symptoms they present. Treatment Study, which is completing 20 years of follow-up of We need to unpack the hidden factors driving not just our enrolled patients. Dr. Higginbotham led the study at the Kellogg patients, but our colleagues, our communities and ourselves.”

The 2018 Farjo Lecturer: In 1993, Dr. Beck founded the JAEB Center for Health Research in Tampa, Florida, a freestanding nonprofit center for Roy W. Beck, MD, PhD clinical and epidemiological research in eye diseases. In his presentation, “My Journey through Clinical Trials in A highlight of Kellogg’s 24th alumni weekend Ophthalmology,” Dr. Beck highlighted a few of the significant was the fourth annual Qais A. Farjo, MD, research projects coordinated by the JAEB Center under his Memorial Lecture, endowed to honor the leadership—a body of work that has resulted in transformation- memory of a talented and revered alumnus al advances in neuro ophthalmology, pediatric eye diseases, and who lost his battle with cancer in 2014. diseases of the cornea and retina. This year’s lecturer was Roy Beck, MD, Reflecting on Dr. Beck’s remarks, Professor Jonathan Trobe, PhD. Dr. Beck came to U-M in 1982 as the first director of Kel- MD, summarized the lecture as “an exercise in modesty” from logg’s neuro ophthalmology service. Between 1982 and 1986, he a leader he described as “without exaggeration, the most also served as the resident education coordinator and directed the celebrated ophthalmic epidemiologist on the face of the earth.” ophthalmology inpatient consultation service.

19 Paying It Forward

From early-career investigators to seasoned faculty leaders, each of us owes a debt to the mentors who have inspired and challenged us along the way. They pave the way for future greatness. Here are five faculty whose achievements serve to inspire us.

Five Kellogg faculty members were honored with prestigious national and international named lectures and awards in 2018. Alan Sugar, MD, MS, delivered the Castroviejo Lecture at the In October, Alan Sugar, MD, delivered the Castroviejo American Academy of Ophthalmology (AAO) Lecture at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago. His presentation traced the development of an ethical framework for clinical research, from notorious scandals like the Tuskegee Syphilis Study to the establishment of principles like informed consent, confi- dentiality and independent oversight. Dr. Sugar also offered several suggestions to address the unique challenges of clinical research in surgical innovation. October’s annual AAO meeting also featured Sayoko Moroi, MD, PhD, who gave the Robert N. Shaffer Lecture. Her remarks, titled, “At the Technological Confluence of Glaucoma Clinical Care and Research,” described both the potential and the challenges of transforming glaucoma management from event-based care—treating glaucoma patients that have already progressed with vision loss and optic nerve damage toward blindness—to precision-based, Sayoko Moroi, MD, PhD gave the Robert N. Shaffer Lecture at the AAO meeting preventive care. At the Alfred W. Bressler Vision Science Symposium, held in New York City in October, Dr. Joshua Stein, MD, MS, received the 2018 Pisart Award and led the annual Pisart Seminar, sponsored by Lighthouse Guild, a leading organiza- tion dedicated to addressing and preventing vision loss. The award recognizes the innovative contributions of early-career vision clinician/scientists. Dr. Stein, a pioneer in applying big data analyses to health research in ophthalmology, spoke on “Tapping into Big Data to Enhance the Care of Patients with Ocular Diseases.”

Alan R. Morse, JD, PhD, President and CEO, Lighthouse Guild, and 2018 Pisart Award recipient Joshua D. Stein, MD, MS

20 Alumni Spotlight

Encouraged by the mentorship they received during their training, two recent Kellogg graduates have gone on to faculty positions at other top institutions. Their accomplishments remind us to never lose sight of the importance of having—and being—great mentors. Kristen Harris Nwanyanwu, MD, MBA, (Residency, 2013), a retinal specialist, is an The President of Academia Ophthalmologica Internationalis, Prof. Gullapalli N. Rao Assistant Professor of Ophthal- presenting the Bernardo Streiff Gold Medal to Paul Lichter, MD, MS mology and Visual Science at the Yale School of Medicine. In June, Professor Emeritus Paul Lichter, MD, MS, received “I’m so grateful for the the Academia Ophthalmologica Internationalis (AOI) Bernardo Streiff Gold Medal at the World Ophthalmology Congress of mentors I had at Kellogg,” the International Council of Ophthalmology in Barcelona, she recounts, “especially Spain. The medal is awarded every four years to an ophthal- Dr. Tom Gardner. We share a passion for stopping mologist who has made an exceptional contribution to the preventable diabetes-related blindness.” Dr. Gardner advancement of ophthalmology globally. His presentation, one continues to mentor Dr. Nwanyanwu through the Yale of more than 40 named lectures he has given over the course of Center for Clinical Investigation Junior Faculty Scholar his remarkable career, was titled “Ethics and Physician-Industry Program. Dr. Nwanyanwu is equally committed to Relationships.” paying it forward, supporting the aspirations of the students and residents on her research team. Andrew Stacey, MD, MS (Residency, 2015) is an As- sistant Professor of Ophthalmol- ogy at the University of Wash- ington and a faculty member at Seattle Children’s Hospital and the Seattle Cancer Care Alli- ance, where he has developed an ocular oncology program— the first ever in the WWAMI region (Washington, Wyoming, Alaska, Montana and Idaho). “I am where I am because of my mentors at Bruce Furr, CO, PhD, gave the Richard G. Scobee Memorial Lecture at the 2018 American Association of Certified Orthoptists (AACO) meeting Kellogg,” he says. Specifically, he points to the support of residency director Shahzad Mian, MD, In October, Dr. Bruce Furr, CO, PhD, gave the Richard and Hakan Demirci, MD, director of the U-M Ocular G Scobee Memorial Lecture. This keynote talk at the 2018 Oncology Clinic. Following the lead of his Kellogg American Association of Certified Orthoptists meeting, held in mentors, Dr. Stacey now actively mentors residents conjunction with the American Academy of Ophthalmology and fellows in the clinic, the operating room and (AAO) meeting. The lecture, titled “Aniseikonia-A 21st Century the lab. Look,” highlighted Dr. Furr’s research on the prevalence of and diagnoses associated with aniseikonia—a significant difference in the perceived size of images between our two eyes.

21 Robin Ali, PhD, and other international researchers received the Champalimaud Vision Award from left to right: Albert M. Maguire, MD Jean Bennett, MD, PhD Samuel G. Jacobson, MD, PhD Michael Redmond, PhD James Bainbridge MD, PhD Robin Ali, PhD

Ophthalmology & Institute of Child Health, Dr. Ali has led Recipients of the 2018 groundbreaking trials demonstrating the safety and efficacy Champalimaud Vision Award of gene therapies for patients with inherited eye diseases. His collaboration with researchers at Kellogg greatly strengthens Include our translational research program. Dr. Robin Ali, PhD Launched in 2006, the Antonio Champalimaud Vision Robin Ali, PhD, F.Med.Sci., Visiting Professor at the Kellogg Award alternates yearly between honoring major scientific Eye Center, is one of seven scientists to share the 2018 breakthroughs in the understanding or preservation of vision Champalimaud Vision Award. (the focus in 2018) and outstanding contributions to the Two independent international teams, from the University alleviation of vision impairment and blindness, primarily in of Pennsylvania and from the University College London, were developing countries. With a prize of one million Euros, it is recognized for developing a gene therapy treatment for patients the largest vision award in the world. with Leber Congenital Amaurosis, a genetic condition that leads “Working with some of the world’s best and brightest helps to childhood blindness. The advancement is the first successful us achieve our mission,” says Kellogg Director Paul Lee, MD, gene therapy for any inherited human disease. JD. “We’re so fortunate to partner with Dr. Ali and his team. At his primary appointment as Professor of Human We congratulate the two teams on this recognition of their Molecular Genetics, University College London Institute of game-changing research.”

At the 2018 Association of University Professors of Ophthalmology Research to Prevent Blindness resident and fellow research forum, former resident and current retina fellow Thomas Wubben, MD, PhD, and former resident and current faculty Nakul Shekawat, MD, were honored as invited speakers. Dr. Shekhawat also received an American Society of Cataract and Refractive Surgery (ASCRS) Foundation Resident Excellence Award.

22 Research to Create Tomorrow's Advances

Research Update

Several major grants were awarded to Kellogg faculty in 2018, Currently, nine Michigan Medicine researchers are funded including the renewal of two major institutional grants and by individual K grants, including Yannis Paulus, MD, who five significant new individual investigator awards, continuing received a K08 grant, and Lindsay DeLott, MD, who received to place Kellogg among the leading centers in the nation a K23 grant, both in 2018. Both Dr. Paulus and Dr. DeLott were in ophthalmic research funding. previously funded by the K12 grant. Kellogg’s National Institutes of Health/National Eye The unrestricted grant funding Kellogg receives from Institute sponsored K12 grant, supporting the Michigan Vision Research to Prevent Blindness (RPB) was also renewed for Clinician-Scientist Development Program, was another five years. In addition, Dr. Jillian renewed for five more years. Overseen by Pro- ”Kellogg is fortunate to be one of a Pearring received a 2018 RPB Career Devel- fessors Thomas Gardner, MD, MS, and Paul opment Award. RPB is the leading non-gov- small group of top centers to hold this Lee MD, JD, the program provides resources ernmental funder of research into conditions and mentorship to help launch the research of range of individual and institutional that threaten sight. Its researchers have been promising early-career investigators. “At any associated with nearly every major break- grants in ophthalmology.” given time, up to two investigators are funded through in this arena in the past 50 years. by the K12 grant,” explains Dr. Gardner, — Paul Lee, MD, JD “These grants support the full spectrum “giving them the time, resources and mentor- of research from genetics to health policy, ship to reach a point where they can compete for individual enabling us to push the frontiers of vision research to treat, cure K grant funding.” Abigail Fahim, MD, PhD, is the newest and prevent vision loss.” explains Director Paul P. Lee, MD, JD. investigator supported by the K12.

23 Steven Abcouwer, PhD, and David Antonetti, PhD

NIH Research Project Grant (R01): Inflammatory Resolution and Vascular Restoration in Diabetic Retinopathy

Diabetic retinopathy and associated diabetic macular edema Unlike impaired foot wound healing in diabetes, however, the are leading causes of blindness in the United States. David retinal vasculature also requires a functioning blood-retinal Antonetti, PhD, and Steven Abcouwer, PhD, have proposed barrier (BRB) that must be restored for proper vessel function. an unique platform for studying how these diseases progress This BRB protects the retina by tightly controlling what can and conducting preclinical testing of potential treatments. enter and leave. By comparing the healing mechanisms of Their research focuses on how diabetes impairs the retina’s normal and diabetic rodents following retinal injury, they hope ability to resolve inflammation and repair itself—specifically, to to identify strategies for overcoming the destructive impact of restore normal blood vessel function after injury. The inability to diabetes on the retina’s ability to combat inflammation and heal properly may be responsible for the buildup of damage in restore the BRB. the diabetic retina. Drs. Antonetti and Abcouwer draw a parallel This effort leverages the special expertise of the Abcouwer between this and another common consequence of diabetes: and Antonetti laboratories in retinal inflammation and the poor wound healing that leads to chronic foot ulcers. blood-retinal barrier, respectively. The close collaboration of This approach is novel in the field of diabetic retinopathy. these laboratories is expected to uncover new insights into the To date, research has focused on how diabetes damages the mechanisms of disease progression and identify new therapeutic retina. These U-M researchers are instead exploring how options to reverse the devastating effects of diabetic retinopathy. inadequate healing may contribute to the disease process.

Rajesh C. Rao, MD

NIH Mentored Clinical Scientist Development Award (K08): Understanding the Epigenetic Mechanisms That Drive Retinal Development

Degenerative retinal diseases like age-related macular degenera- tion (AMD) are blinding disorders with few treatment options. In AMD, a disease that affects 10 million Americans, degenera- tion of photoreceptor cells leads to vision loss. One current tissue regeneration strategy for AMD is the transplantation of photoreceptors (light-sensing cells) derived from pluripotent stem cells. Pluripotent stem cells can develop into many types of cells. In this multi-step strategy, pluripotent stem cells are coaxed to specifically become retinal precursors, on gaining a better understanding of how stem cell-derived which later give rise to photoreceptors. But this approach is retinal precursors arise. Specifically, the project uses a stem inefficient, donor-dependent and still poorly understood. cell-based platform to study the role of the Mll1 complex, an Rajesh Rao, MD, Assistant Professor of Ophthalmology important epigenetic protein that “switches on” genes necessary and Visual Sciences and Pathology and an Emerging Scholar at for retinal development. It is hoped that the knowledge gained the A. Alfred Taubman Medical Research Institute, has devel- from this endeavor will lead to new stem cell-based therapies to oped a three-year mentored career development project focused restore vision.

24 RPB Career Development Award: Jillian Pearring, PhD Understanding how molecules are delivered to the light-sensing organelle of photoreceptor cells.

Human vision takes shape in the retina, a thin and transparent piece of neural tissue lining the back of the eye. Light entering the eye is captured by the rod- and cone-shaped outer segments of photoreceptor cells in the retina. The light-sensing outer segment compartment contains a specific set of proteins involved in capturing light and transforming it into electrical signals to be processed by the brain. Defects in the delivery of these select proteins are responsible for many forms of inherited retinal degenerative diseases, including retinitis pigmentosa, a blinding disease affecting nearly two million people worldwide. funded by a generous Career Development Grant from Research The lab of Dr. Jillian Pearring, PhD, is working to under- to Prevent Blindness (RPB). stand the cellular mechanisms that guide protein transport and RPB is the leading voluntary health organization supporting delivery to the outer segment in healthy photoreceptors and research to prevent, treat or eradicate all diseases that threaten how defects in these processes result in retinal degeneration. vision. Researchers supported by RPB have been associated with What her team discovers may guide the development of future nearly every major breakthrough in vision research in the past therapies to treat patients with retinal disease. Her work is 50 years.

David Musch, PhD, MPH NIH Exploratory/Developmental Research Grant Award (R21): Glaucoma progression—modeling its trajectory and contributing factors: evidence from AGIS and CIGTS

The extent and rate of visual field progression is an important measure of a glaucoma patient’s response to treatment. A panel convened by the National Eye Institute (NEI) to study glaucoma and optic neuropathies called for experts in the field to standard- ize instruments and data collection methods as well as improve statistical methods that determine the progression of disease. David Musch, PhD, MPH, Professor of Ophthalmology and Visual Sciences in the Medical School and Professor of Epidemiology in the School of Public Health, is stepping up to The project, which will employ advanced statistical tech- that challenge using this grant. His team of experts includes niques, has two distinct aims: 1) to compare numerous meth- Brenda Gillespie, PhD, Associate Professor of Biostatistics in ods of modeling the progression of visual field loss in order to the U-M School of Public Health and Associate Director of the identify the best ones; and 2) to investigate the importance of the U-M Center for Statistical Consultation and Research, Kellogg type of visual field defects documented in two landmark NEI- Senior Statistician Leslie Niziol, MS, and Paul Lichter, MD, supported clinical trials—the Advanced Glaucoma Intervention Professor Emeritus. Joseph Caprioli, MD of UCLA and Paul Van Study and the Collaborative Initial Glaucoma Treatment Study. Veldhuisen, PhD, of the Emmes Corporation are also involved.

25 Abigail Fahim, MD, PhD, Receives Clinical Scientist Institutional Career Development Program Award

Kellogg Clinical Assistant Professor Abigail Fahim, MD, PhD, has been awarded a Clinical Scientist Institutional Career Development Program Award from the National Institutes of Health. With this award, which supports early-career investi- Choroideremia is caused by defects in a single gene, CHM, gators working within interdisciplinary research programs, which helps transport proteins to the correct locations in cells. Dr. Fahim will occupy one of two positions in the Michigan “Our hypothesis is that a disruption in this transport process Vision Clinician Scientist Development Program K12 grant changes the characteristics of RPE cells in choroideremia,” overseen by Professor Thomas Gardner, MD. explains Dr. Fahim. Using a technology for the genetic manipu- Dr. Fahim’s lab is investigating the connection between lation of stem cells called clustered regularly interspaced short the retinal pigment epithelium (RPE) and the development of palindromic repeats, her team has generated RPE cells with a inherited diseases of the retina, notably choroideremia, an early choroideremia defect to compare their function with that of onset blinding disease for which there is no treatment. normal cells. The RPE is a layer of cells situated between the light-sensing “I see patients who will be blinded by inherited retinal photoreceptor cells and the choroid, a collection of blood vessels diseases like choroideremia for which I can do nothing,” that supplies oxygen and nutrients to the retina. While much is Dr. Fahim says. “This research will help us understand the known about the many ways the RPE supports photoreceptor genetic changes that drive these diseases, and will provide a cells, far less is known about how the RPE interacts with the platform for testing new treatment strategies—it’s the next choroid. step in giving these patients hope.”

NIH Institutional Training Grant (T32): Supporting pre-and post-doctoral fellows training in vision research at the University of Michigan This grant funding will continue to support the University of Michigan’s long-standing tradition of training graduate students and postdoctoral fellows for careers in vision research. The centerpiece of this effort is the National Eye Institute supported Vision Research Training Program (VRTP). Recently renewed with continuous funding extended to 20 years, the VRTP serves to create a cohesive community of vision scientists at U-M, recruiting outstanding pre-and post-doctoral fellows and providing breadth in research training and professional development to keep pace with opportunities for careers in The NIH institutional training grant helps prepare graduate students and vision research. The VRTP is enhanced by the Michigan Vision postdoctoral fellows for successful careers in research Clinician Scientist Development (K12) Program, one of only six such programs in the United States. The program is directed by Peter Hitchcock, PhD, Professor Members of the training faculty are funded, productive of Ophthalmology and Visual Sciences and Professor of Cell scientists and experienced mentors whose research portfolios and Developmental Biology in the School of Medicine and include both basic and translational projects. Most hold primary Associate Dean for Academic Programs and Initiatives in the appointments in the Department of Ophthalmology and Visual Rackham Graduate School. In his role as graduate dean, Dr. Sciences, but the team also includes faculty in the departments Hitchcock provides administrative oversight for 26 bioscience of Cell and Developmental Biology, Biomedical Engineering, PhD programs and the 1,400 postdoctoral research fellows and Molecular, Cellular and Developmental Biology. training at U-M.

26 Philanthropy is Crucial for Our Success

27 Faculty Named to Two Endowed Professorships

Ceremonies recognize the generosity and In April, Cagri G. Besirli, MD, PhD, shared his gratitude foresight of Mary and Edwin Meader and of for a long-term investment in the Kellogg Eye Center. He was the Skillman Foundation. named the Skillman Career Development Professor of Pediatric Ophthalmology, a professorship that grew out of a gift made K. Thiran Jayasundera, MD, was named the Paul R. Lichter more than 30 years ago. Professor of Ophthalmic Genetics in November. At his installa- The Detroit-based Skillman Foundation made a multifac- tion ceremony, he expressed his appreciation for a gift made eted contribution to children’s eye care in the late 1980s. by Mary and Edwin Meader, who established the endowed Dr. Besirli, a physician-scientist whose research reaches across professorship in 1991. broad areas of pediatric ophthalmology, Dr. Jayasundera is a vitreoretinal sur- is advancing scientific knowledge and care geon whose far-reaching research program related to retinal diseases. He is a leader focuses on autoimmune and inherited reti- in studies implementing telemedicine nal degenerations. He was the first surgeon for the care of premature infants for the in the United States to implant the Argus detection of retinopathy of prematurity. II device after FDA approval—a ground- His laboratory research seeks to restore breaking new technology, often called a diseased retinal cells. bionic eye, that can transform the lives of “Professorships are a hallmark of some patients with retinal dystrophies. academic medicine,” says Paul P. Lee, The Meaders, who passed away in the MD, JD, F. Bruce Fralick Professor and late 2000s, made many gifts to U-M. In Christopher U. Light, Jr., the grandson of Chair of the Department of Ophthalmol- creating this professorship, they honored Rachel Mary Upjohn Meader ogy and Visual Sciences and Director of Paul R. Lichter, MD, who served as chair the W.K. Kellogg Eye Center. “They exist of the department for more than 33 years. in perpetuity, forever driving research progress and enabling Dr. Jayasundera is the third person to hold the professor- faculty to devote time to educational and leadership activities. ship. The first was Paul A. Sieving, MD, PhD, who today is the We are deeply thankful to those who provide this extraordinary director of the National Eye Institute, and the second was John and enduring support.” R. Heckenlively, MD, professor emeritus of Ophthalmology and Visual Sciences at U-M.

Thiran Jayasundera, MD, FACS, and Paul Lichter, MD, MS Carol Bradford, MD, MS, Cagri Besirli MD, PhD, and Paul Lee, MD, JD

28 KELLOGG EYE CENTER HEALTH SYSTEM MICHIGAN MEDICINE UNIVERSITY OF MICHIGAN

DEPARTMENT OF EMERGENCY MEDICINE UNIVERSITY OF MICHIGAN HEALTH SYSTEM MICHIGAN MEDICINE UNIVERSITYVictors OF MICHIGAN for Michigan, Victors for Vision

Historic campaign raises more than $63 million for Sylvia Rieling and Don Sherman joined us for a campaign finale event in November eye disease care, research, and education. Accelerating Progress and Promise As part of the Victors For Michigan Campaign, more than 6,000 donations to the W.K. Kellogg Eye Center resulted in $63.3 million to support Kellogg's work, As of Nov. 6, total campaign gifts to the making it the most successful fundraising effort in the eye center's history. Kellogg Eye Center included:

The Victors for Michigan campaign began in 2013 and ended Dec. 31, 2018. Kellogg • $37.6 million for research aimed at surpassed our $50 million goal by 26.6 percent, achieving campaign initiatives to: curing, preventing, and more effectively treating eye disease • Accelerate breakthrough discovery • Invest in visionary leaders • $14 million for faculty support, enabling • Create revolutionary environments for patient care, research, and education us to recruit and retain the best ophthal- • Invent new models of patient care and education mologists and vision scientists

Campaign highlights included: • $11.7 million for programmatic support, • Annual fund donors made contributions to the W.K. Kellogg Eye Center that including gifts to fuel innovation in educa- together helped develop a new drug to save cells essential to vision. tion, patient care, clinical research, and international ophthalmology • In celebrating the life of its founder, a foundation supported glaucoma faculty and research, investments that today are funding research that will help physicians better tailor treatments to specific patients.

• A forward-looking couple made a targeted contribution to eye cancer, enabling the director of our growing program to pursue innovative research through national and international partnerships.

• Alumni made generous gifts and bequests to launch an Alumni Legacy Fund that will help Kellogg remains a leader in the field for generations to come.

“Contributions made during the campaign have propelled us forward, bringing Friends of the Kellogg Eye Center Lisa and Jon Gandelot new treatments to patients, new technology and tools to faculty, and new ways of learning to our trainees,” says Paul P. Lee, MD, JD, F. Bruce Fralick Professor and With Gratitude to Our Campaign Chair of the Department of Ophthalmology and Visual Sciences and Director of Leadership Council the W.K. Kellogg Eye Center. “Individuals, families, and foundations are helping us The following volunteers played a key role in realize the full potential of what is possible. Working together, there's no end to our success. We appreciate their guidance, what we can accomplish.” generosity, and partnership. “I’m thrilled at the outcome of the campaign and greatly impressed with the prog- ress that is being made in discovery science, clinical research, and patient care,” says • Richard A. Manoogian, Honorary Chair Richard A. Manoogian, honorary chair of the Kellogg Eye Center Campaign Leader- • Grant H. Beard ship Council. “As someone who saw my father struggle with eye disease in the later • Eric F. Conn years of his life, it gives me great hope for the future. It is an honor to partner with so • Richard A. Garfinkel, MD many people who share a commitment to saving sight. We are all victors for vision.” • Carleton H. Griffin, JD (1928-2014) • David H. Grossman To learn more about supporting the Kellogg Eye Center, or to tell us about • Richard F. Gutow, MD your personal mission to save sight, please contact our development team • Leonard G. (Larry) Miller at 734-763-1723 or visit www.kellogg.umich.edu/giving. • Richard N. Witham

29 KELLOGG'S NEW FACULTY

Brittany Boland, OD Samantha Gagnon, OD Sean Hansen, MD Scott Lawrence, MD Clinical Instructor Clinical Instructor Clinical Instructor Clinical Associate Professor Optometry Optometry Comprehensive Ethiopia

Matthew McKee, MD Colleen Podd, OD Traci (Thielen) Seng, OD Nakul Shekhawat, MD, PhD Amy Zhang, MD Clinical Instructor Clinical Instructor Clinical Instructor Clinical Lecturer Clinical Assistant Professor Comprehensive Optometry VA Comprehensive Glaucoma

New faculty not photographed: Coye Carver, MD, FACS, Adjunct Clinical Faculty, Michael Mandell, MD, Adjunct Clinical Faculty

Upcoming CME Programs

Each year, Kellogg offers an informative series of continuing medical education (CME) programs designed to share new approaches to the diagnosis and management of eye disease across subspecialties. These are our upcoming programs:

Saturday, June 1, 2019 91st Annual Spring Postgraduate Conference Cornea 8 a.m.–5 p.m. Kellogg Eye Center Ann Arbor, Michigan

Thursday, June 13, 2019 For more information or to register for these programs, 35th Annual Research Day visit: www.umkelloggeye.org

Friday, September 27, 2019 For questions, contact Jennifer Burkheiser, CME Coordinator, Fall Alumni Day at (734) 763-2357 or [email protected].

30 2018 GRADUATING RESIDENTS

Tatiana Deveney, MD Joseph Grubbs, JR., MD, MPH Sean Hansen, MD Tyson Kim, MD, PHD Graduate Chief Resident and Lecturer Comprehensive ophthalmology Clinical Lecturer Cornea Fellowship Kellogg Eye Center Virginia Eye Institute Kellogg Eye Center University of Miami Ann Arbor, MI Richmond, VA Ann Arbor, MI Bascom Palmer Eye Institute

Lev Prasov, MD, PHD David Sanders, MD, MPH Nakul Shekhawat, MD, MPH Ophthalmic Genetics Fellow Glaucoma Fellowship Clinical Lecturer National Eye Institute Oregon Health & Science University Kellogg Eye Center Bethesda, MD Portland, OR Ann Arbor, MI

2018 GRADUATING CLINICAL FELLOWS

NICHOLAS BEHUNIN, MD ERIN BOESE, MD TALAL DERANI, MD Cornea Glaucoma Neuro-Ophthalmology St. George Eye Center University of Iowa University of Toledo St. George, UT Iowa City, IA Toledo, OH

KARA DOLEZAL, MD SHAWN SHAFIK GAPPY, MD THAO Phuong LE, MD JASON HOOTON, MD Pediatric Ophthalmology Pediatric Ophthalmology Pediatric Ophthalmology Cornea University of Cincinnati Central Eye Care, P.C. Eye Associates Northwest, P.D. Premier Eye Care of Eastern Idaho Cincinnati, OH Hazel Park and Rochester Hills, MI Seattle, WA Idaho Falls, ID

THERESE SASSALOS, MD KIRA SEGAL, MD MERINA THOMAS, MD Uveitis Fellowship Eye Plastic and Orbital Surgery Retina Kellogg Eye Center Weill Cornell Medical College Oregon Health and Sciences University Ann Arbor, MI New York, NY Portland, OR

31 2018 FIRST YEAR POST-DOCTORAL FELLOWS

Ashutosh Phadte Nath Madhu Dr. Phadte is from Mumbai, India and Dr. Madhu is from India. She is working the University of Missouri-Columbia. He in the laboratory of Patrice Fort, PhD on is working in the laboratory of Patrice therapeutic aspects of αA-crystallins on Fort, PhD on the role of post-translational diabetic retinopathy. modifications onα A–crystallins and their role in neuroinflammation.

Qitao Zhang Jorge Martinez-Marquez Dr. Zhang is from China. He is working Dr. Martinez-Marquez comes from in the laboratory of Jason Miller, MD PhD the laboratory of Mara Duncan at the on the pathological effects of lipofuscin University of Michigan. He is working (autofluorescent granules accumulated in in the laboratory of Jillian Pearring, PhD aged RPE cells). on membrane trafficking in vertebrate photoreceptor cells.

Omar Moinuddin Dr. Moinuddin is a recent medical school graduate of the Oakland University William Beaumont (OUWB) School of Medicine. He is working in the labora- tory of Cagri Besirli MD, PhD on the metabolic reprogramming of glycolysis as a neuroprotective strategy to enhance photoreceptor survival under chronic retinal stress.

Kellogg faculty, alumni, trainees and family members gathered for the Michigan Society of Eye Physicians and Surgeons (MiSEPS) 50th Annual Conference, held at the Grand Hotel on Mackinac Island. The meeting was organized by Chair Dr. Denise Kim and Co-Chair Dr. Manjool Shah. Dr. Theresa Cooney of Kellogg serves as President of MiSEPS. Kellogg’s Dr. Christopher Hood is Regional Director, with Dr. Jerome Finkelstein serving as Delegate to the Michigan State Medical Society.

32 2018 FIRST-YEAR RESIDENTS Jara Crear, MD BS – Engineering and Economics Program in Liberal Medical Education Brown University MD – Alpert Medical School, Brown University

Emily Eton, MD BS – Integrative Physiology University of Iowa MD – Harvard Medical School

Olivia Killeen, MD BS – International Relations Carleton College Michigan Alumnus Honored MD – University of Michigan Medical School for Humanitarian Efforts in Africa Sana Qureshi, MD BS – Political Science New York University Michigan Medicine faculty and alumni continue to make a MD – Albert Einstein College of Medicine difference in how ophthalmology is practiced in every corner of the world. One inspiring example is the tireless work of John Cropsey (MD 2005), treating patients and training providers in some of the most remote areas on the African continent. Carin Rojas, MD Dr. Cropsey's work was recognized in October when BS – English, United States Naval Academy he became the fifth recipient of the University of Michigan MD – Feinberg School of Medicine Medical School Alumni Association’s Michigan Medicine Northwestern University Alumni Society Distinguished Humanitarian Award. Dr. Cropsey earned both his undergraduate and medical degrees at the U-M and completed his residency at the

Wills Eye Hospital in Philadelphia. In 2009, after networking Emily Schehlein, MD with others interested in working in Africa, he gathered BS – Chemistry/Biology, a multi-specialty team to practice in Africa. Loyola University Maryland His team’s passion for educating African healthcare MD – University of Maryland School of Medicine professionals has grown into a partnership with Hope Africa University in Bujumbura, Burundi, to develop that medical school’s teaching hospital, Kibuye Hope Hospital. Dr. Cropsey and his wife, Jessica, now lead a team of 50 expatriates at Annie Wu, MD Kibuye. BS – Biology For the 2017-18 academic year, Dr. Cropsey returned Brown University to Kellogg for a sabbatical year, providing comprehensive MD – Alpert Medical School and cataract surgical services to patients and inspiration to Brown University students and colleagues.

33 FACULTY HONORS AND RECOGNITION JULY 1, 2017 — SEPTEMBER 30, 2018

Steven F. Abcouwer, PhD Wayne T. Cornblath, MD Associate Editor in Chief, Metabolic Syndrome and Obesity: Best Doctors in America Targets and Therapy, Diabetes Topic Chair, Annual Meeting Neuro-Ophthalmology/Neuro-Otology, Academic Editor, Journal of Ophthalmology American Academy of Neurology Consulting Editors Board, Diabetes Abstract Review Committee for Annual Meetings, American Academy Editorial Board, American Journal of Physiology: Endocrinology of Neurology and Metabolism Walsh Committee, North American Neuro-Ophthalmology Society Editorial Board, Journal of Clinical & Experimental Ophthalmology Editorial Board, Journal of Clinical & Cellular Immunology John M. Cropsey, MD Editorial Board, Journal of Diabetes Research David Paton, MD Lecture, Wills Eye Academic Global Ophthalmology, Grant Reviewer, Welcome Trust DBT India Alliance Fellowship Review Wills Eye Hospital Grant Reviewer, Participant, Anonymization Project, Center for Scientific Review Research Review, Sherry H. Day, OD National Institutes of Health Board Member, Academic Medical Center Optometrist, Special Study Section, Diseases and Pathophysiology of the Visual System Study Interest Group, American Academy of Optometry Section, Center for Scientific Review, National Institutes of Health Lindsey B. De Lott, MD Study Section, Diseases and Pathophysiology of the Visual System Abstract Review Committee, American Academy of Neurology, (DPVS) Study Section, National Neuro-Ophthalmology/Neuro-Otology Subsection Institutes of Health Subsection Committee, Working Group, American Academy of Member, University of Missouri Chemical Engineering Academy of Neurology Neuro Ophthalmology/Neuro-Otology Distinguished Alumni Planning Committee, Frank B. Walsh Society, North American Commercial Relations Committee, Association for Research in Vision Neuro-Ophthalmology Society and Ophthalmology Monte A. Del Monte, MD David A. Antonetti, PhD Castle Connolly Top Doctors Editorial Board, Diabetes Hakan Demirci, MD Editorial Board, Tissue Barriers Grant reviewer, PRESTIGE Marie Curie post-doc fellowships Steven M. Archer, MD programme, International Student and Researcher Mobility, Castle Connolly Top Doctors The French National Agency American Orthoptic Council, American Ophthalmological Society Joshua R. Ehrlich, MD Bylaw Committee Ethics Committee Editorial Board, Ophthalmic Epidemiology Program Committee, Ad hoc reviewer, Special Emphasis Panel on Immune System, Ad Hoc International Committee the Brain, and Visual System, National Institutes of Health Chair, AGS CARES Committee, American Glaucoma Society Brenda L. Bohnsack, MD, PhD Susan G. Elner, MD Castle Connolly Top Doctors Best Doctors in America Editorial Board, Journal of Pediatric Ophthalmology and Strabismus Pediatric Uveitis Task Force, American Association for Pediatric Castle Connolly Top Doctors Ophthalmology and Strabismus Victor M. Elner, MD, PhD Kari E. Branham, MA Castle Connolly Top Doctor Scientific Advisory Board, Foundation Fighting Blindness Inaugural Dortzbach Lecture, North American Society of Academic Orbital Surgeons Grant M Comer, MD, MS Jerome I. Finkelstein, MD Best Doctors in America Best Doctors in American Theresa M. Cooney, MD WQE Standard Setting Panel, American Board of Ophthalmology Best Doctors in America Board of Governors, Michigan Society of Eye Physicians and Surgeons Castle Connolly Top Doctors President and President Elect, Michigan Society of Eye Physicians and Surgeons

34 FACULTY HONORS AND RECOGNITION JULY 1, 2017 — SEPTEMBER 30, 2018

Patrice E. Fort, PhD Mark W. Johnson, MD Editorial Board, Journal of Clinical and Experimental Ophthalmology Castle Connelly Top Doctors Editorial Board, PlosOne Best Doctors in America Guest Editor, Frontiers in Genetics; Frontiers in Neuroscience Editorial Board, American Journal of Ophthalmology Grant Reviewer, American Diabetes Association's Research Editorial Board, The Journal of Vitreoretinal Diseases, Retina Grant Reviewer, Research and Training Grant, Fight for Sight Editorial Board, Retinal Physician Grant Reviewer, Vidi Program, The Netherlands Organisation for Lorand Johnson Lecture, Case Western Reserve University Hospital, Scientific Research Cleveland Ophthalmological Society Grant Reviewer, Development Research Projects Program, INBRE J. Robert Meyers Lecture, Penn State University, Penn State College (IDeA Network of Biomedical of Medicine Research Excellence), National Institutes of Health Philip P. Ellis Lecture, University of Colorado School of Medicine Ad-hoc Reviewer, Study Section, Disease and Patholphysiology J. Donald M. Gass Memorial Lecture, Ophthalmic Photographers Society of the Visual System, National Eye Associate Examiner, American Board of Ophthalmology Institute, National Institutes of Health Life Achievement Honor Award, American Academy of Ophthalmology Program Committee, American Academy of Ophthalmology Retina Bruce A. Furr, MD Subspecialty Day Editorial board, Journal of Binocular Vision and Ocular Motility Retina Society: Editorial board, Journal of Pediatric Ophthalmology and Strabismus Immediate Past President Nominating Committee Chair Christopher Gappy, MD Awards Committee Chair Best Doctors in America Program Committee Castle Connelly Top Doctors The Macula Society: Treasurer Thomas W. Gardner, MD Credentials Committee Castle Connolly Top Doctors Editorial board, Clinical Diabetes and Endocrinology Alon Kahana, MD, PhD Editorial board, Associate Editor, Acta Ophthalmologica Best Doctors in America Editorial board, Diabetes Care Editorial board, Oculoplastic Surgery Section, Ocular Surgery News Grant Reviewer, Icelandic Research Fund Drs. Frank Nesi and Evan Black Lectureship, Department of Chair, Restoring Vision Moonshot Workshop, Juvenile Diabetes Ophthalmology, Kresge Eye Institute, Wayne State University Research Foundation Richard Dortzbach Inaugural Lecture, Annual Meeting, North American Society of Academic Orbital Surgeons Peter F. Hitchcock, PhD Adrian and Gladys Drouhilet Lecture, Ophthalmology & Visual Sciences, Academic Editor, PLoS ONE University of Texas-Houston Grant reviewer, Special Emphasis Panel, Immune System, Brain, Founding President, North American Society of Academic Orbital and the Visual System, National Institutes of Health Grant Reviewer, Surgeons Retina France Chair, Scientific Advisory Committee, American Society of Ophthalmic Board Member, External Advisory Board, Collaborative Opportunities Plastic and Reconstructive Surgery for Success in Mentoring of Students Chair-Elect, Thesis Committee, American Society of Ophthalmic Plastic (PNW-COSMOS), Alliances for Graduate Education and Professoriate, and Reconstructive Surgery National Science Foundation, Pacific Northwest Alliance FDA Approval, Investigational Device Exemption for the Slit Stent II Lacrimal Stent Bret A. Hughes, PhD Education Committee, American Society of Ophthalmic Plastic and Castle Connolly Top Doctors Reconstructive Surgery Study Section, NEI Center Core Grants for Vision Research (P30), Program Directors Committee, American Society of Ophthalmic Plastic National Eye Institute, National Institutes of Health and Reconstructive Surgery

Kanishka (Thiran) Jayasundera, MD Ariane D. Kaplan, MD Associate Editor, BMC Ophthalmology Review Committee, Basic and Clinical Science Course Book 1, Inventor, U.S. Patent awarded 2/2018: Automated measurement American Academy of Ophthalmology of changes in retinal, Retinal pigment epithelial, or choroidal disease, 9898818 Harjeet Kaur, MD Castle Connolly Top Doctors Denise A. John, MD Fellowship Compliance Subcommittee, American Glaucoma Society

35 FACULTY HONORS AND RECOGNITION JULY 1, 2017 — SEPTEMBER 30, 2018

Paul P. Lee, MD, JD David C. Musch, PhD (cont.) Castle Connolly Top Doctors Cornea Preferred Practice Pattern Guidelines Panel, American Advisory Committee, JAMA Ophthalmology Academy of Ophthalmology David W. Parke, MD Lecture, Connecticut Society of Eye Physicians Methodologist, Preferred Practice Patterns Committee, American David Paton Medical Lecturer, Baylor College of Medicine Academy of Ophthalmology Paul A. Webber Lecture, Havener Eye Institute, Ohio State University Methodologist, Ophthalmic Technology Assessment Committee, Clement McCulloch Lecture, Li Ka Shing Knowledge Institute, American Academy of Ophthalmology University of Toronto Chair, Data & Safety Monitoring Boards: Stephen J. Munz Lecture, Kaiser Permanente 35th Annual Glaukos Corporation, Laguna Hills, CA (iStent Supra for glaucoma Ophthalmology Symposium treatment) Advisory Board, Hoskins Center for Patient Safety and Quality InnFocus, LLC, Miami, FL (MicroShunt for glaucoma treatment) Member at Large, Board of Directors, American Glaucoma Society Neurotech & MacTel Group (CNTF treatment for macular telangiectasia) Board of Directors, American Board of Ophthalmology Opthea, Ltd, Victoria, Australia (VEGF-C/D trap treatment for Chair, American Board of Ophthalmology neovascular AMD) Trustee-at-Large, Association of University Professors of Ophthalmology Refocus, Inc., Dallas, TX (scleral implant for presbyopia treatment) Board of Trustees, Society of Heed Fellows Aura Biosciences, Inc., Cambridge, MA (AU-011 for treatment of Board of Directors, NAEVER and AEVER Board choroidal melanoma) Telemedicine Working Group, American Academy of Ophthalmology Chengdu Kanghong Biotechnology Co., Ltd., China (Conbercept treatment for neovascular AMD) Paul R. Lichter, MD Member, Data & Safety Monitoring Committees: Best Doctors in America NEI Intramural Branch Clinical Trials, National Eye Institute, National Castle Connolly Top Doctor Institutes of Health Steven M. Podos, MD, Lecture, Mt. Sinai Icahn School of Medicine META-MUST Uveitis Treatment Trials, National Eye Institute, National Vice President, International Council of Ophthalmology Foundation Institutes of Health 2018 Bernardo Streiff Gold Medal, Academia Ophthalmological ADVISE Uveitis Treatment Trial, National Eye Institute, National Institutes Internationalis of Health Stopping Anti-TNF Agents in Rheumatoid Arthritis (STARA), National Shahzad I. Mian, MD Institute of Arthritis and Musculoskeletal and Skin Diseases, National Best Doctors in America Institutes of Health & MedStar Health Research Institute Castle Connelly Top Doctors Editorial Board, Cornea Christine C. Nelson, MD Past-President, Program Director’s Council, Association of University Board Trustee, American Society of Ophthalmic Plastic and Professors in Ophthalmology Reconstructive Surgery Co-director, Cornea Society Fellows Summit Board Member, World Association of Eye Hospitals Co-director, Cornea Day, American Society of Cataract and Refractive Surgery Yannis Paulus, MD Co-chair, Accreditation Board, Eye Bank Association of America Editorial Board, International Journal of Ophthalmic Research Program Committee, American Academy of Ophthalmology Editorial Board, International Journal of Ophthalmic & Eye Science Residency Review Committee, Accreditation Council for Graduate Executive Committee, Technical Group on Therapeutic Laser Medical Education Applications, Optical Society of America Fundraising Committee, International Society for Eye Research Sayoko E. Moroi, MD, PhD Fellow, American College of Surgeons Harold Gifford, Jr., MD Lecture, Truhlsen Eye Institute, University Member, Macula Society of Nebraska Medical Center United States Patent, 15/584,317, Method and Apparatus for removing microvessels David C. Musch, PhD Editorial Board member: Jillian N. Pearring, PhD JAMA Ophthalmology Career Development Award, Research to Prevent Blindness Retina Eye and Vision Howard R. Petty, PhD Grant Reviewer, Medical Research Fund, United Kingdom Co-Chief Editor, Frontiers in Cell and Developmental Biology, Grant Reviewer, Research Grants Council, Hong Kong Molecular Medicine Study Section, Special Emphasis Panel, National Eye Institute, National Institutes of Health Donald G. Puro, MD, PhD Advisory Group, US Project, Cochrane Collaboration Eyes and Best Doctors in America Vision Group

36 FACULTY HONORS AND RECOGNITION JULY 1, 2017 — SEPTEMBER 30, 2018

Rajesh C. Rao, MD Debra A. Thompson, PhD Best Doctors in America Editorial Board, Experimental Eye Research Castle Connolly Top Doctors Grant Reviewer, BrightFocus, Harrington Discovery Institute Editor, Social Media, Ophthalmology Editor, Social Media, Ophthalmology Retina Jonathan D. Trobe, MD Grant Reviewer, Epidemiology Merit Review Panel (EPID), Merit Castle Connolly Top Doctors and Career Development Awards Programs, Office of Research and Development, Clinical Science Sara L. Weidmayer, OD Research & Development Service, Department of Veterans Affairs Editorial Review Board, Review of Optometry Grant Reviewer, Million Veteran Program (SPLM/MVP) Veterans Regional Vice-Chair, Admittance Committee, American Academy Administration (VA) Merit, Department of Veterans Affairs of Optometry Grant Reviewer, Biomedical Laboratory Research &Development Service, Department of Veterans Affairs Jennifer S. Weizer, MD Inducted Member, Retina Society Best Doctors Resident Education Committee, American Academy of Ophthalmology Anjali R. Shah, MD Advisory Board, Eye Care Innovator Track, American Medical Kwoon Y. Wong, PhD Group Association Editorial Board, Current Eye Research Grant Reviewer, Royal Society Te Ap¯arangi (New Zealand) Nakul Shekhawat, MD, MPH Grant Reviewer, Swiss National Science Foundation 2018 Resident Excellence Award, American Society of Cataract Grant Reviewer, CAREER grant review, National Science Foundation and Refractive Surgery Study Section, R01 Special Emphasis Panel “Retinal Circuitry, Signaling and Physiology,” National Institutes of Health Terry J. Smith, MD Best Doctors in America Sarah K. Wood, OD Merit Award, University of Missouri School of Medicine Secretary and Treasurer, Glaucoma Section, American Academy of Optometry H. Kaz Soong, MD Assistant Editor, Cornea Maria A. Woodward, MD, MS Associate Editor, International Journal of Eye Banking Joshua D. Stein, MD Colleen Conway Grace MD Memorial Lectureship, University of Castle Connolly Top Doctors Maryland Editorial Board, JAMA Ophthalmology Chair, Research Committee, Eye Bank Association of America Board of Directors, American Glaucoma Society Research, Regulatory & External Scientific Relations Committee, Board of Directors, National Quality Forum American Academy of Ophthalmology Joseph E. Koplowitz Memorial Lecture, Wilmer Eye Center Telemedicine Working Group, American Academy of Ophthalmology Pisart Award in Vision Science, Lighthouse Guild

Alan Sugar, MD, MS Best Doctors in America Editorial Board, and Editor-in Chief, Journal of the Cornea Society, Cornea Grant Reviewer, National Medical Research Council of Singapore Troutman Award Committee, Cornea Society Eye Bank Association of America: Medical Advisory Board, Research Committee, and Paton Award Committee

Bradford L. Tannen, MD Editor, Journal of Ocular Biology Associate Editor, and Editorial Board, Case Reports, American Journal of Ophthalmology Case Reports, American Journal of Ophthalmology

37 2018 KELLOGG EYE CENTER FACULTY, RESIDENTS, AND FELLOWS Faculty of the Department of Ophthalmology and Visual Sciences All of us at the Kellogg Eye Center are committed to improving lives through curing, Steven Abcouwer, PhD Paul Lee, MD, JD Robin Ali, PhD, FMedSci Helios Leung, OD, PhD preventing and treating eye disease. David Antonetti, PhD Paul Lichter, MD, MS Steven Archer, MD Philip Lieu, MD Bernadete Ayres, MD Cheng-mao Lin, PhD Our guiding principles are teamwork, caring, Cagri Besirli, MD, PhD Michael Lipson, OD, FAAO Jill Bixler, MD Xuwen Liu, MD, PhD innovation and integrity. Brenda Bohnsack, MD, PhD April Maa, MD Brittany Boland, OD Matthew Mc Kee, MD Kari Branham, MS, CGC Shahzad Mian, MD Kuen-Ren (Roland) Chen, PhD Sayoko Moroi, MD, PhD Executive Officers of Michigan Medicine Grant Comer, MD, MS David Musch, PhD, MPH Marschall S. Runge, MD, PhD Theresa Cooney, MD Mikiko Nagashima, PhD Executive vice president for medical affairs, dean Wayne Cornblath, MD Christine Nelson, MD, FACS University of Michigan Medical School, CEO, Michigan Medicine John Cropsey, M.D. Paula Anne Newman-Casey, MD, MS Sherry Day, OD, FAAO Yannis Paulus, MD David A. Spahlinger, MD Lindsey De Lott, MD Jillian Pearring, PhD President, Michigan Medicine, and executive vice dean for clinical Monte Del Monte, MD Howard Petty, PhD affairs University of Michigan Medical School Karen DeLoss, OD Colleen Podd, OD Patricia D. Hurn, PhD Hakan Demirci, MD Shreya Prabhu, MD Dean, School of Nursing Laxmi Devisetty, MD Donald Puro, MD, PhD Tatiana Deveney, MD Rajesh Rao, MD Courtney Dewey, OD Alan Robin, MD The Regents of the University of Michigan Joshua Ehrlich, MD, MPH Julie Rosenthal, MD Jordan B. Acker, Michael J. Behm, Mark J. Bernstein, Angela Elam, MD Frank Rozsa, PhD Paul W. Brown, Shauna Ryder Diggs, Denise Ilitch, Susan Elner, MD Gary Sandall, MD Ron Weiser, Katherine E. White, Mark S. Schlissel (ex officio) Victor Elner, MD, PhD Jill Schafer, OD Abigail Fahim, MD, PhD Traci Seng, OD Annual Report Team Cherie Farkash, OD Anjali Shah, MD Editors: Julie Rosenthal, MD, Christopher Gappy, MD Jerome Finkelstein, MD Manjool Shah, MD Patrice Fort, PhD Nakul Shekhawat, MD, MPH Writers: MargaretAnn Cross, Rosemary Clandos, Shelley Zalewski Carlton Foster, OD Roni Shtein, MD, MS Design and Art Direction: David Murrel Bruce Furr, CO, PhD Frank Sloan, PhD Philip Gage, PhD Terry Smith, MD Photographers: Samantha Gagnon, OD Michael Smith-Wheelock, MD Michigan Photography: Eric Bronson, Daryl Marshke, Christopher Gappy, MD H. Kaz Soong, MD Scott Soderberg, Austin Thomason; U-M Kellogg Eye Center Thomas Gardner, MD, MS William Sray, MD Department of Ophthalmology and Visual Sciences: Tim Costello, Paul Grenier, OD Joshua Stein, MD, MS Tim Steffens; Department of Communication: Bryan A. McCullough; Sean Hansen, MD Jeffrey Stern, MD, PhD Nicole Haley Photography: Nicole Haley Peter Hitchcock, PhD Alan Sugar, MD, MS Christopher Hood, MD Jeffrey Sundstrom, MD, PhD FOR PATIENT APPOINTMENTS, PLEASE CALL 734.763.8122 Bret Hughes, PhD Bradford Tannen, MD, JD Diane Jacobi, OD Sally Temple, PhD K. Thiran Jayasundera, MD Debra Thompson, PhD For additional copies, please contact us: Vanitha Jeyaraj, MD Jonathan Trobe, MD University of Michigan Denise John, MD, FRCSC Joshua Vrabec, MD Department of Ophthalmology and Visual Sciences Mark Johnson, MD Grace Wang, MD, PhD W.K. Kellogg Eye Center Shannon Joseph, MD, MSc Sara Weidmayer, OD 1000 Wall Street Alon Kahana, MD, PhD James Weiland, PhD Ann Arbor, Michigan 48105 Shivani Kamat, MD Jennifer Weizer, MD www.umkelloggeye.org Ariane Kaplan, MD Adrienne West, MD Harjeet Kaur, MD Donna Wicker, OD Naheed Khan, PhD Kwoon Wong, PhD Denise Kim, MD Sarah Wood, OD, MS Zvi Kresch, MD Maria Woodward, MD, MS Amy Lagina, OD Rebecca Wu, MD Scott Lawrence, MD David Zacks, MD, PhD University of Michigan W.K. Kellogg Eye Center Department of Ophthalmology and Visual Sciences 1000 Wall Street Ann Arbor, MI 48105

Kellogg Among Nation’s Best in Eye Care

The University of Michigan Kellogg Eye Center is proud OPHTHALMOLOGY to be ranked in the top 10 in the country by U.S. News # & World Report—recognizing our outstanding care for 8 IN THE NATION patients with complex eye conditions. Kellogg has seen extraordinary growth in all aspects of patient care, research and education since the department was established in 1872. Every day, our clinicians, scientists, trainees and staff work together to shape the future of eye care and vision science.

~ Our Purpose ~ To improve lives through curing, preventing and treating eye disease 2018 U.S. NEWS & WORLD REPORT’S “BEST HOSPITALS”